Status: Not yet recruiting
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Inflammasome TherapeuticsUpdated: Feb 9, 2026
Eligibility criteria
Diagnosis of definite, probable, laboratory-supported probable, or possible ALS... [+2]
Inability to follow the study protocol, based on the investigator's assessment. [+15]